Letter to the Editor: Update to: Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

J Prev Alzheimers Dis. 2024;11(4):1178-1179. doi: 10.14283/jpad.2024.147.
No abstract available

Publication types

  • Letter

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Humans
  • Randomized Controlled Trials as Topic*

Substances

  • aducanumab
  • Antibodies, Monoclonal, Humanized